Nanobiotix is trading 10.01% down at $28.04 on October 1, 2026; no clear company-specific announcement explaining the decline surfaced.
- Investor-relations materials list the September 14 clinical update as the latest release.
- The decline coincides with Treasury yields at multi-decade highs and a midday report of major U.S. indexes lower as rising yields pressured stocks; a direct macro cause for Nanobiotix’s drop is unconfirmed.